- Abstract viewed - 1732 times
- PDF downloaded - 1120 times
- Declaration of Conflict of Interest downloaded - 0 times
- Copyright Assignment Form downloaded - 0 times
- Figure 1 downloaded - 0 times
- Figure 2a downloaded - 0 times
- Figure 2b downloaded - 0 times
- Figure 2c downloaded - 0 times
- Figure 2d downloaded - 0 times
- Figure 2e downloaded - 0 times
- Figure 2f downloaded - 0 times
- Figure 3a downloaded - 0 times
- Figure 3b downloaded - 0 times
- Figure 3c downloaded - 0 times
- Figure 3d downloaded - 0 times
- Figure 3e downloaded - 0 times
- Figure 3f downloaded - 0 times
- Figure 3g downloaded - 0 times
Copyright
© Clujul Medical, 2019
Affiliations
Cristian Popita
The Oncology Institute “Prof. Dr. Ion Chiricuţă”, Cluj-Napoca, Romania,
“Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Anca Raluca Popita
Department of Radiology and Medical Imaging, The Oncology Institute “Prof. Dr. Ion Chiricuţă”, Cluj-Napoca, Romania
“Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Adela Sitar-Taut
New Blue Life Medical Center, Cluj-Napoca, Romania
Bogdan Petrut
Department of Urology, The Oncology Institute “Prof. Dr. Ion Chiricuţă”, Cluj-Napoca, Romania,
“Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Bogdan Fetica
Department of Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuţă”, Cluj-Napoca, Romania
Ioan Coman
Department of Urology, Clinical Municipal Hospital, Cluj-Napoca, Romania,
“Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
How to Cite
1.5-Tesla Multiparametric-Magnetic Resonance Imaging for the detection of clinically significant prostate cancer
Abstract
Background and aims. Multiparametric-magnetic resonance imaging (mp-MRI) is the main imaging modality used for prostate cancer detection. The aim of this study is to evaluate the diagnostic performance of mp-MRI at 1.5-Tesla (1.5-T) for the detection of clinically significant prostate cancer.
Methods. In this ethical board approved prospective study, 39 patients with suspected prostate cancer were included. Patients with a history of positive prostate biopsy and patients treated for prostate cancer were excluded. All patients were examined at 1.5-T MRI, before standard transrectal ultrasonography–guided biopsy.
Results. The overall sensitivity, specificity, positive predictive value and negative predictive value for mp-MRI were 100%, 73.68%, 80% and 100%, respectively.
Conclusion. Our results showed that 1.5 T mp-MRI has a high sensitivity for detection of clinically significant prostate cancer and high negative predictive value in order to rule out significant disease.